Get started
Author

Yuka Lewis

ORCID: 0009-0003-5761-947X
Observed ORCID: 0009-0003-5761-947X
OpenAlex ID: A5011114443
WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al. · Cancer Immunology Research · 1
964 Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity
2025 · Tiziana M Cafarelli, Pamela Aderhold-Camiré, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Development of conditionally active IL-10 INDUKINE TM molecules for the treatment of inflammatory bowel disease
2024 · Jenna Sullivan, Pamela Aderhold, et al. · The Journal of Immunology · 1
Abstract 4078: WTX-712, a conditionally active IL-21 INDUKINETM molecule, induces a strong anti-tumor phenotype through a differentiated mechanism
2024 · Jenna M. Sullivan, Pamela A. Aderhold, et al. · Cancer Research · 1
Abstract 1829: Generation of IL-21 INDUKINETM molecules for the treatment of cancer
2023 · Jenna M. Sullivan, Pamela A. Aderhold, et al. · Cancer Research · 1
Supplemental Figure 3 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Figure 1 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Figure 5 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Data from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Figure 2 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Figure 4 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Table 2 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Table 3 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
Supplemental Table 1 from WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike “Non-Alpha” Muteins
2026 · Christopher J. Nirschl, Kulandayan K. Subramanian, et al.
1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment
2023 · Christopher J Nirschl, Heather R Brodkin, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 15
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type